XKRX
092040
Market cap14mUSD
Jul 10, Last price
1,215.00KRW
1D
5.19%
1Q
-36.98%
Jan 2017
-94.46%
IPO
-96.84%
Name
Amicogen Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Amicogen, Inc. is an industrial biotechnology firm established in 2000, with its headquarters located in Jinju-si, South Korea, conducting business both domestically and globally. The company engineers and supplies a diverse range of specialized enzymes, such as CX and SP, that serve critical functions across the pharmaceutical, food, chemical, and energy sectors. In addition to enzymes, Amicogen produces innovative bio-ingredients, including N-acetylglucosamine for enhancing skin moisture and joint well-being; pinitol/D-chiro-inositol; collagen peptides and tripeptides aimed at promoting skin and general health; chitoslim and chitosan oligosaccharides; various lactic acid bacteria; as well as fucoxanthin, curezyme, food enzymes, and bamboo salt. Furthermore, the company markets its own consumer lines, K-nutra for health-related products and KeyClean for disinfectants, and also provides protein purification resins.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||